FMP

FMP

Enter

VNDA - Vanda Pharmaceutical...

photo-url-https://images.financialmodelingprep.com/symbol/VNDA.png

Vanda Pharmaceuticals Inc.

VNDA

NASDAQ

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

4.37 USD

0 (0%)

Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

248.17M

268.68M

254.38M

192.64M

198.77M

189.76M

181.15M

172.93M

165.09M

157.6M

Revenue %

-

8.27

-5.32

-24.27

3.18

-4.54

-4.54

-4.54

-4.54

Operating Cash Flow

51.77M

64.21M

31.98M

12.8M

-15.76M

21.27M

20.31M

19.39M

18.51M

17.67M

Operating Cash Flow %

20.86

23.9

12.57

6.65

-7.93

11.21

11.21

11.21

11.21

Cap Ex

-1.79M

-552k

-679k

-383k

-490k

-622.78k

-594.53k

-567.56k

-541.81k

-517.24k

Cap Ex %

-0.72

-0.21

-0.27

-0.2

-0.25

-0.33

-0.33

-0.33

-0.33

Free Cash Flow

49.98M

63.66M

31.3M

12.42M

-16.25M

20.65M

19.71M

18.82M

17.97M

17.15M

Weighted Average Cost Of Capital

Price

4.37

Beta

Diluted Shares Outstanding

58.15M

Costof Debt

3.91

Tax Rate

After Tax Cost Of Debt

3.22

Risk Free Rate

Market Risk Premium

Cost Of Equity

Total Debt

12.36M

Total Equity

254.11M

Total Capital

266.47M

Debt Weighting

4.64

Equity Weighting

95.36

Wacc

7.1

Build Up Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

248.17M

268.68M

254.38M

192.64M

198.77M

189.76M

181.15M

172.93M

165.09M

157.6M

Operating Cash Flow

51.77M

64.21M

31.98M

12.8M

-15.76M

21.27M

20.31M

19.39M

18.51M

17.67M

Cap Ex

-1.79M

-552k

-679k

-383k

-490k

-622.78k

-594.53k

-567.56k

-541.81k

-517.24k

Free Cash Flow

49.98M

63.66M

31.3M

12.42M

-16.25M

20.65M

19.71M

18.82M

17.97M

17.15M

Wacc

7.1

7.1

7.1

7.1

7.1

Pv Lfcf

19.28M

17.19M

15.32M

13.66M

12.17M

Sum Pv Lfcf

77.62M

Terminal Value

Growth In Perpetuity Method

Long Term Growth Rate

Wacc

7.1

Free Cash Flow T1

17.84M

Terminal Value

575.76M

Present Terminal Value

408.63M

Intrinsic Value

Enterprise Value

486.25M

Net Debt

-89.96M

Equity Value

576.21M

Diluted Shares Outstanding

58.15M

Equity Value Per Share

9.91

Projected DCF

9.91 0.559%

DCF Levered

Download Excel

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep